glp-1 inhibitor drugs New Guidelines for Type 2 Diabetes in 2025 GLP-1 Drugs: Where We Are
Description
Peak GLP-1 increases were significantly higher (~32%) after RYGB at both follow-ups (p<0.05)
Pfizer's obesity pill danuglipron has not progressed to Phase 3 trials and is not approved in the UK
Experiencing hair loss while taking GLP-1 medications
GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.
No nausea
Despite these findings, a clear link has yet to be established, and much of the evidence remains inconsistent
